These findings suggest that HVEM-Fc suppressed tumor invasiveness by reprogramming tumor-associated macrophages (TAMs) towards the M1 phenotype and enhancing their anti-tumor functions, thus highlighting HVEM-Fc as a promising new cancer immunotherapy agent (Fig. 5O-R). The gene discussed is TNFRSF14; the disease is cancer.